Berzosertib

Global ATR Protein Inhibitors Market Set to Revolutionize Cancer Treatment and Expand into Neurodegenerative and Infectious Diseases - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, BAY, Alzheimer's disease, AstraZeneca, Cholangiocarcinoma, Genetic testing, Ovarian cancer, Therapy, Parkinson's disease, Breast, Emotional dysregulation, Research, Virus, Clinical trial, Berzosertib, COVID-19, Viral, Ataxia telangiectasia and Rad3 related, Radiation, HIV-1, DNA repair, Vertex Pharmaceuticals, Bone marrow, Cancer, Investment, ATR, Patient, Ataxia–telangiectasia, DNA, Pharmaceutical industry, Vaccine, Bayer, Merck

A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

Key Points: 
  • A promising frontier in cancer pharmaceutical research, the inhibition of Ataxia telangiectasia and Rad3 related kinase (ATR kinase) is poised to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.
  • Pipeline Analysis: The report offers insights into the global ATR protein inhibitors clinical pipeline, categorized by company, indication, and phase.
  • Development Trends: ATR inhibitors are expanding their scope to include neurodegenerative diseases and viral infections, opening new avenues for treatment.
  • This innovative approach to targeting DNA damage response pathways has the potential to revolutionize cancer treatment and extend its reach to neurodegenerative and infectious diseases.

EMD Serono to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

Retrieved on: 
Sunday, September 12, 2021
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Hospitals, Clinical Trials, Science, Biotechnology, Nursing, FDA, Health, Other Science, BAVENCIO® (avelumab), Tepotinib, Berzosertib, Bintrafusp Alfa, EMD Serono, Inc., Merck KGaA, Darmstadt, Germany, BAVENCIO® (AVELUMAB), TEPOTINIB, BERZOSERTIB, BINTRAFUSP ALFA, EMD SERONO, INC., MERCK KGAA, DARMSTADT, GERMANY

EMD Serono is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer.

Key Points: 
  • EMD Serono is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer.
  • Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month.
  • Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.
  • The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

Retrieved on: 
Monday, April 12, 2021
Nursing, Biotechnology, Managed care, Health, Radiology, Pharmaceutical, Oncology, Research, Hospitals, Science, Clinical trials, Berzosertib, Clinical medicine, Medicine, Ovarian cancer, Health, Gemcitabine, Small Cell Lung Cancer, Berzosertib, Merck

Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type,3 and it is the lead candidate in Merck\xe2\x80\x99s DNA Damage Response (DDR) inhibitor portfolio.

Key Points: 
  • Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type,3 and it is the lead candidate in Merck\xe2\x80\x99s DNA Damage Response (DDR) inhibitor portfolio.
  • Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
  • Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
  • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.

EMD Serono Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

Retrieved on: 
Monday, April 12, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Berzosertib, Ovarian cancer, Clinical medicine, Gemcitabine, Health, Ataxia telangiectasia and Rad3 related, Medicine

Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type,3 and it is the lead candidate in EMD Serono\xe2\x80\x99s DNA Damage Response (DDR) inhibitor portfolio.

Key Points: 
  • Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type,3 and it is the lead candidate in EMD Serono\xe2\x80\x99s DNA Damage Response (DDR) inhibitor portfolio.
  • Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
  • Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
  • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.